Dr. Debra Odink is the President and Chief Development Officer of Thryv Therapeutics. With over 30 years of experience, she has played a pivotal role in the pharmaceutical development of both large and small molecules across multiple therapeutic areas.

Dr. Odink began her career at Roche, where she worked in manufacturing process development and the characterization of several early-stage programs. She then transitioned into the start-up, venture-backed biotech sector, starting with Peninsula Pharmaceuticals, where she advanced a sterile-filled antibiotic from pre-clinical development to NDA, ultimately leading to its acquisition by Johnson & Johnson.

As Chief of Technical Operations at Anthera Pharmaceuticals, Dr. Odink advanced multiple products ranging from cardiovascular indications to autoimmune disorders into Phase 3. At Eiger Biopharmaceuticals, as Senior Vice President of Technical Operations, she led the advancement of small molecule, peptide and biologic therapeutics into four rare disease programs, one of which was recently approved. Most recently, at SiteOne Therapeutics, she served as Chief Development Officer, where she was instrumental in advancing a novel non-opioid pain therapeutic into clinical trials.

Dr. Odink holds a Ph.D. in Chemistry from the University of California, Davis, and a B.S. in Chemistry from California State University, Stanislaus.